Are electronic signatures acceptable and auditable?

Yes. Electronic signatures meet legal standards under the ESIGN Act (15 U.S.C. §7001) and UETA where adopted, provided intent, consent, attribution, and retention requirements are satisfied; include ESIGN consumer disclosure if the policy collects consumer-facing consents and retain a reproducible audit trail.

When to report suspected diversion to authorities

Report suspected loss, theft, or diversion promptly. Significant thefts require DEA Form DEA-106 and immediate notification to the DEA and state board per federal and state rules. Timely reporting preserves enforcement cooperation and reduces regulatory penalties; consult counsel for major incidents.

What records must be retained and for how long?

Maintain perpetual inventory logs and incident files per federal minima: financial/tax records three years (IRC §6501(a)), HIPAA-related health records six years (45 CFR §164.530(j)), and retain RON audio-video recordings for state-mandated periods (commonly five to ten years).

Do I need a BAA for eSignature vendors handling PHI?

Yes, HIPAA requires a Business Associate Agreement when the vendor handles PHI. Vendor must support HIPAA compliance and security controls; include BAA, encryption, access controls, and breach notification obligations in contract.

Can policy attestations be collected remotely?

Yes; attestation signatures are generally valid electronically under ESIGN/UETA if intent, consent, attribution, and retention are documented. For notarized acknowledgements or RON, follow state RON rules and retain required audio-video and journal records.

How often should the policy be reviewed and updated?

Review annually at minimum and after any incident, regulatory change, or accreditation finding. Document revisions with effective dates and version control. Major regulatory or DEA guidance changes may require immediate update and retraining.

Electronic Signature
Templates
Healthcare
Healthcare Controlled Substances Policy

Healthcare Controlled Substances Policy

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

HEALTHCARE CONTROLLED SUBSTANCES POLICY

Facility Name: Policy Number:

Effective Date:

Next Review Date:

Department / Unit Responsible:

Purpose and Scope

This policy establishes the standards and procedures governing the procurement, storage, prescribing, dispensing, administration, monitoring, documentation, disposal, and reporting of controlled substances within the facility. It applies to all licensed practitioners, pharmacists, nursing staff, technicians, and any personnel with access to controlled substances.

Definitions

For purposes of this policy, "controlled substance" refers to drugs classified under applicable federal and state controlled substances schedules. "Authorized prescriber" means a practitioner licensed and registered to prescribe controlled substances. "Diversion" means unlawful distribution or use of controlled substances by personnel or patients.

Authorized Personnel and Credentials

Only personnel documented and credentialed by the facility may prescribe, transcribe, dispense, or administer controlled substances. Each authorized prescriber must maintain current licensure, federal registration where required, and documentation of training in controlled substance management.

List of Authorized Prescribers (name, license, DEA as applicable):

Prescribing and Dispensing Standards

Prescribers shall perform a documented clinical assessment establishing a legitimate medical purpose prior to initiating controlled substance therapy. The medical record must contain diagnosis, treatment rationale, dosage and quantity limits, anticipated duration, and alternatives considered. Prescriptions must conform to applicable law and facility-defined limits.

Maximum initial prescription duration (days):

Prescribers shall use the lowest effective dose and quantity. Non-controlled alternatives should be considered and documented. The facility prohibits automatic refill authorization without clinical re-evaluation.

Patient Assessment, Consent and Treatment Agreements

Prior to initiating long-term controlled substance therapy, the prescriber shall obtain informed consent that includes the risks and benefits of therapy, potential for dependence, and the patient’s responsibilities. When applicable, a written treatment agreement shall be executed and retained in the medical record.

Patient agreement template or location of template:

Monitoring and Follow-up

Clinical follow-up shall be scheduled and documented at intervals appropriate to the medication and patient risk. Prescribers must document efficacy, adverse events, adherence, and use of objective monitoring such as urine drug testing when clinically indicated.

Recommended follow-up interval (days):

Prescription Drug Monitoring Program (PDMP) and External Checks

Prescribers and dispensing clinicians shall consult applicable prescription monitoring resources in accordance with law and facility requirements prior to initiating and periodically during controlled substance therapy. Documentation of the query and key findings must be maintained in the medical record.

PDMP / External check required prior to first controlled prescription:

Frequency of mandated PDMP queries:

Inventory, Storage and Security

Controlled substances shall be stored in secured, locked storage that restricts access to authorized personnel. Inventory controls shall include perpetual records for schedule II and periodic reconciliations for other schedules. Losses or discrepancies must be investigated and documented immediately.

Primary storage location: Inventory custodian (name and contact): Inventory reconciliation frequency:

Waste, Disposal and Return

Disposal of controlled substances shall follow secure, documented procedures ensuring unreadable destruction and chain-of-custody. Returns and take-back events shall be handled in accordance with regulatory standards and facility protocols.

Authorized disposal procedure reference or summary:

Loss, Diversion and Incident Reporting

Any actual, suspected, or attempted diversion or loss shall be reported immediately to the inventory custodian, facility compliance officer, and appropriate law enforcement or regulatory authorities as required by law. An internal investigation shall commence within 24 hours.

Incident reporting contact and escalation steps:

Training, Education and Competency

All clinical and pharmacy personnel with responsibilities for controlled substances shall complete facility-mandated training on safe prescribing, diversion prevention, secure handling, documentation, and legal obligations at hire and at least annually thereafter.

Required training frequency:

Audits, Compliance and Discipline

The facility will conduct periodic compliance audits, including random audits of controlled substance inventories, prescribing patterns, and medical records. Noncompliance may result in corrective action up to suspension of prescribing privileges, termination, and reporting to licensing or law enforcement authorities where required.

Record retention period (years):

Confidentiality and Medical Record Documentation

All documentation concerning controlled substances shall be maintained in the patient’s medical record consistent with confidentiality requirements. Access to these records shall be limited to personnel with a clinical need to know.

Legal and Regulatory Compliance

This policy requires compliance with federal and state controlled substances statutes and regulations. Nothing in this policy authorizes conduct prohibited by law. The facility will cooperate with lawful regulatory and enforcement inquiries.

Schedules Covered

The policy applies to all controlled substance schedules handled by the facility. Select applicable schedules maintained on-site:

Schedule II Schedule III Schedule IV Schedule V

Policy Review and Amendments

This policy shall be reviewed at intervals defined above or sooner to reflect changes in law, clinical practice, or regulatory guidance. Amendments require approval by the designated authority.

Authority approving amendments (name/title):

Acknowledgment of Policy Implementation

All staff with responsibilities under this policy must acknowledge review of the policy and completion of any required training. The facility will maintain acknowledgments in personnel files.

Acknowledgment retention location or process:

Authorized Facility Representative:

Title:

Signature:

Date:

What the Healthcare Controlled Substances Policy Covers

Healthcare Controlled Substances Policy establishes organizational rules and procedures for prescribing, storing, dispensing, inventorying, documenting, and disposing of controlled medications within a healthcare setting. It describes roles and responsibilities for prescribers, pharmacists, nurses, and designated custodians; details recordkeeping and audit requirements; and aligns internal controls with federal and state regulations including the Controlled Substances Act and DEA guidance, plus applicable privacy and retention obligations under HIPAA. Use this policy to reduce diversion risk, ensure regulatory compliance, and provide a consistent framework for staff training and incident response.

Why a Formal Policy Matters for Compliance and Safety

A clear Healthcare Controlled Substances Policy reduces diversion, supports patient safety, and documents compliance with DEA and state controlled-substance regulations. It creates auditable processes for prescribing and disposal, clarifies accountability, and supports defensible recordkeeping during inspections or litigation.

Departments and Roles That Typically Use This Policy

Typical users who implement or complete this policy include clinical leadership, pharmacy directors, and compliance officers.

Hospitals — pharmacy leadership, prescribers, nursing units, supply chain, and compliance teams responsible for controlled drug oversight.
Outpatient clinics — prescribers, clinical pharmacists, and office managers who manage prescriptions and inventory.
Long-term care and behavioral health facilities — medication nurses, medical directors, and supply custodians.

Smaller practices, telemedicine providers, and third-party pharmacies may adapt policy sections to meet their operational and licensing requirements.

Core Components to Include in the Policy

Essential sections of a Healthcare Controlled Substances Policy define controls, responsibilities, recordkeeping, security, audit, and incident response expectations across clinical and pharmacy operations.

Scope and Purpose

Define the policy scope, covered medications (by DEA schedule), facility locations, roles, and exceptions; state objectives for diversion prevention, patient safety, and regulatory compliance and monitoring.

Roles & Responsibilities

List responsibilities for prescribers, pharmacists, nurses, inventory custodians, and compliance staff, including prescribing limits, verification steps, audits, disciplinary actions, and documentation procedures.

Inventory Controls

Require perpetual inventory, controlled substance logs, reconciliation frequency, tamper-evident storage, access restrictions, and procedures for discrepancies and loss reporting within specified timeframes.

Prescription Process

Specify prescription authorization, electronic prescribing standards, controlled-substance prescribing limits, verification for verbal orders, refill protocol, and use of Prescription Drug Monitoring Programs (PDMPs) in applicable jurisdictions.

Security & Storage

Describe secure storage requirements (locked cabinets, controlled access), alarm and surveillance expectations, key control, and measures for transporting controlled substances between departments or facilities safeguards.

Documentation & Audits

Define required records, retention periods, audit schedules, incident investigation steps, reporting templates, and access to documentation for inspections by DEA or state regulatory agencies and corrective actions.

Step-by-Step: Implementing or Updating the Policy

Follow these steps to implement or update your Healthcare Controlled Substances Policy across clinical and pharmacy workflows.

01

Assess Risks: Inventory current practices and diversion risk points.
02

Draft Policy: Use regulatory references and institutional procedures.
03

Train Staff: Deliver role-specific training and documentation.
04

Audit & Revise: Schedule periodic audits and policy updates.

Configuring Digital Workflows for the Policy

Configure the policy template, approval routing, and electronic signature settings before issuing the Healthcare Controlled Substances Policy digitally.

Field	Configuration
Template Version Control	Enable versioning and effective date validation.
Signer Order	Set sequential or parallel signing.
Authentication Level	Choose email, SMS, or ID verification.
Retention Settings	Auto-archive signed copies and logs.

Where Completed Policies Are Filed or Sent

Typical routing for completed policies includes internal records, pharmacy record systems, legal counsel, and submission to licensing or accrediting bodies if required.

Internal Records: Store in quality management system.
Pharmacy System: Upload to controlled substances module.
Compliance File: Provide to compliance officer and counsel.
Regulatory Submission: Submit to state board when required.

Technical Requirements for eSignatures and eSubmission

For electronic completion, ensure your e-signature platform supports secure authentication, tamper-evident records, and HIPAA-compliant handling where necessary.

Authentication Options: Email, SMS, or KBA available.
Audit Trail: Full timestamped event log.
Integrations: EHR, document management, and cloud.

Essential Data Elements and Records to Maintain

Patient Identifiers: Name, DOB, medical record number.

Medication Details: Drug name, strength, dosage form.

Prescription Orders: Prescriber, order date, quantity.

Inventory Records: Stock counts, lot numbers, reconciliations.

Incident Reports: Loss, theft, diversion investigations.

Access Logs: User activity, timestamps, IP addresses.

Consequences of Incomplete or Noncompliant Policies

Regulatory Fines: Civil penalties and monetary fines.

License Sanctions: Suspension or revocation risk.

Criminal Liability: Felony charges for diversion.

Civil Litigation: Malpractice or wrongful death suits.

Accreditation Impact: Survey findings can downgrade status.

Patient Safety: Medication errors and harm.

Key Timelines and Reporting Expectations

Key timelines include inventory reconciliation cadence, mandatory reporting windows for loss or theft, staff training intervals, and scheduled policy reviews.

Inventory Reconciliation:

At least monthly reconciliations recommended.

Loss/Theft Reporting:

Report to DEA/state board within one business day.

Staff Training Frequency:

Initial and annual refresher training required.

Policy Review Cycle:

Review and update at least annually.

Audit Schedule:

Formal internal audit quarterly or as risk dictates.

Practical Tips for Clear, Enforceable Policy Documents

Adopt clear workflows, limit access, standardize forms, and use electronic signatures to improve accuracy and auditability of controlled substances management.

Use electronic inventory and reconciliation systems

Implement perpetual electronic inventory with barcode or RFID tracking, schedule automated reconciliations, and generate tamper-evident reports. Electronic logs reduce transcription errors and provide time-stamped audit trails for inspections and internal reviews.

Define prescriber authorization and delegation limits

Establish written thresholds for quantity and frequency, require second clinician review for outliers, and document delegation rules. Clear limits reduce inappropriate prescribing, simplify audits, and support disciplinary action when policies are breached.

Train staff with role-specific modules and assessments

Deliver initial and annual training tailored to prescribers, pharmacists, nurses, and custodians. Include scenario-based exercises on diversion, documentation, and emergency reporting. Maintain attendance records and competency attestations for regulatory inspection.

Perform regular audits and corrective actions

Schedule internal audits, reconcile variances promptly, and document corrective actions with responsible parties and deadlines. Track repeat findings and escalate unresolved issues to compliance leadership to reduce systemic risks and demonstrate corrective steps to regulators.

Illustrative Use Cases in Healthcare Settings

Real-world examples show how institutions adapt the Healthcare Controlled Substances Policy to operational realities and regulatory expectations.

Regional Hospital

A 350-bed regional hospital revised its controlled substances policy after a diversion incident uncovered gaps in inventory reconciliation and role assignments.

Implemented daily reconciliations and restricted access.
The hospital reduced discrepancies by automated counting, required two-person verification for high-risk removals, and provided retraining; documentation showed improvements during state inspection and met DEA expectations for corrective action follow-through.

Community Clinic

A small community clinic standardized electronic ordering and integrated PDMP checks into its prescribing workflow to reduce unnecessary controlled-substance prescriptions.

Adopted e-prescribing and staff training.
The clinic documented reduced prescribing of high-risk agents, improved record completeness, and used audit logs to respond quickly to pharmacy inquiries, satisfying state board reviews and enhancing patient safety metrics.

eSignature Vendor Comparison for Healthcare Policy Workflows

Comparison of common eSignature vendors and key pricing or compliance features relevant to Healthcare Controlled Substances Policy workflows.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial, no credit card required	Varies by vendor and plan	Varies by vendor and plan	Varies by vendor and plan	Varies by vendor and plan
Bulk Send	Yes — available in Business Premium and up	Yes — available on select plans	Yes — available with higher tiers	Yes — includes bulk send features	No — bulk send not available
Audit Trail	Yes — full audit trail and certificates	Yes — full audit trail	Yes — full audit trail	Yes — audit log available	Yes — audit features available
HIPAA Compliant	Yes (BAA available)	Yes (BAA available)	Yes (BAA available)	No	No
Envelope Cap	No envelope cap; unrestricted usage	Limited to 100 envelopes per user per year	Varies by plan	Varies by plan	Varies by plan

Frequently Asked Questions About the Policy

Answers to common questions about drafting, executing, and maintaining a Healthcare Controlled Substances Policy in U.S. healthcare settings.

Need help? Contact support

Are electronic signatures acceptable and auditable?
Yes. Electronic signatures meet legal standards under the ESIGN Act (15 U.S.C. §7001) and UETA where adopted, provided intent, consent, attribution, and retention requirements are satisfied; include ESIGN consumer disclosure if the policy collects consumer-facing consents and retain a reproducible audit trail.
When to report suspected diversion to authorities
Report suspected loss, theft, or diversion promptly. Significant thefts require DEA Form DEA-106 and immediate notification to the DEA and state board per federal and state rules. Timely reporting preserves enforcement cooperation and reduces regulatory penalties; consult counsel for major incidents.
What records must be retained and for how long?
Maintain perpetual inventory logs and incident files per federal minima: financial/tax records three years (IRC §6501(a)), HIPAA-related health records six years (45 CFR §164.530(j)), and retain RON audio-video recordings for state-mandated periods (commonly five to ten years).
Do I need a BAA for eSignature vendors handling PHI?
Yes, HIPAA requires a Business Associate Agreement when the vendor handles PHI. Vendor must support HIPAA compliance and security controls; include BAA, encryption, access controls, and breach notification obligations in contract.
Can policy attestations be collected remotely?
Yes; attestation signatures are generally valid electronically under ESIGN/UETA if intent, consent, attribution, and retention are documented. For notarized acknowledgements or RON, follow state RON rules and retain required audio-video and journal records.
How often should the policy be reviewed and updated?
Review annually at minimum and after any incident, regulatory change, or accreditation finding. Document revisions with effective dates and version control. Major regulatory or DEA guidance changes may require immediate update and retraining.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now